The company provides contract analytical testing and calibration services for industries including pharmaceuticals, food, agriculture, and environmental monitoring to ensure regulatory compliance and product quality.
The company lacks a durable moat as evidenced by low average net margins of 1.3% and a return on capital (7.1%) that likely sits below its cost of capital. While regulatory accreditations provide a license to operate, they do not offer pricing power in a fragmented market where the company remains a small player.
Earnings are largely reinvested into laboratory instrumentation and infrastructure, but these investments have historically generated poor returns on equity (2.2% average). The company carries significant debt (D/E 1.34) and does not pay dividends, prioritizing survival and maintenance over shareholder distributions.
The company's collapse was driven by a lethal combination of high leverage and operational fragility. The 2025 ransomware attack proved to be a harbinger of systemic internal control failures, leading to prolonged regulatory scrutiny and a loss of client trust. As interest rates remained sticky, the thin interest coverage ratio evaporated, forcing the company to take on more expensive debt to service existing obligations. With net margins already near zero, the business could not absorb rising labor and compliance costs, eventually resulting in a liquidity crunch that wiped out equity holders while the promoters continued to draw high remuneration.
RichFakir rates Choksi Laboratories Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Choksi Laboratories Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Choksi Laboratories Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Choksi Laboratories Ltd's fair value is about ₹12 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →